AURA3 clinical trial showed significant superiority of osimertinib over platinum-based chemotherapy in advanced NSCLC patients with T790M mutation in EGFR gene and with progression on prior EGFR TKIs treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.